HealthCare Global Enterprises (NSE:HCG) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:HCG HealthCare Global Enterprises Ltd NSE:HCG
79 GF Score
Price ₹600.40
GF Value ₹576.14
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is HealthCare Global Enterprises Research & Development?

HealthCare Global Enterprises NSE:HCG -2.25% 79 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:HCG with a GF Score™ of 79/100 and a GF Value™ of ₹576.14 (Fairly Valued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. HealthCare Global Enterprises's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

HealthCare Global Enterprises  (NSE:HCG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

HealthCare Global Enterprises Research & Development Related Terms

HealthCare Global Enterprises Research & Development Historical Data

* Premium members only.

The historical data trend for HealthCare Global Enterprises's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HealthCare Global Enterprises Research & Development Chart

HealthCare Global Enterprises Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HealthCare Global Enterprises Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:HCG
79GF Score
HealthCare Global Enterprises Ltd NSE:HCG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HealthCare Global Enterprises Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
HealthCare Global Enterprises (NSE:HCG) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on HealthCare Global Enterprises and its competitors.
Is HealthCare Global Enterprises' Research & Development too high?
HealthCare Global Enterprises' current Research & Development is ₹0 Mil. Overall, HealthCare Global Enterprises has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HealthCare Global Enterprises' Research & Development compare to HCA and THC?
HealthCare Global Enterprises' Research & Development of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on HealthCare Global Enterprises and its competitors. HealthCare Global Enterprises's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthCare Global Enterprises stock overvalued right now?
Based on GuruFocus' analysis, HealthCare Global Enterprises (NSE:HCG) is currently considered Fairly Valued. The stock's GF Value™ is ₹576.14, compared to a current price of ₹600.40 — trading 4.2% above its estimated fair value. The current Research & Development is ₹0 Mil. HealthCare Global Enterprises' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For HealthCare Global Enterprises (NSE:HCG), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HealthCare Global Enterprises (NSE:HCG) Overvalued in 2026?

Based on GuruFocus' analysis, HealthCare Global Enterprises stock appears to be overvalued. The current stock price of ₹600.40 is trading 4.2% above its estimated GF Value™ of ₹576.14. GuruFocus considers HealthCare Global Enterprises to be Fairly Valued.

Key valuation signals for NSE:HCG:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹576.14 vs. price of ₹600.40 (4.2% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the NSE:HCG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HealthCare Global Enterprises Business Description

Other Exchanges 539787:India
Address Mission Road, No. 3, Ground Floor, Tower Block, Unity Building Complex, Bengaluru, KA, IND, 560027
HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company's operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
79GF Score

Get the complete analysis for NSE:HCG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹600.40
Price
₹576.14
GF Value